

**MEDICAL POLICIES**

JULY 2018

**Medical Policies - July 2018**

Our Medical Policies have been updated. Below is a summary of changes for July.

**NEW**

[LUXTURNA™ \(Voretigene neparvovec\) — Medicaid](#)

**REVISED**[Insulin Delivery Devices and Continuous Glucose Monitoring \(CGM\) Systems](#)

- For long term usage; combined the section for single external insulin delivery infusion pumps with the section for combined CGM/Insulin-delivery devices (with the addition of real-time monitoring devices) to create a single section with simplified criteria.
- Added that combination devices that include a home blood glucose monitor combined with a blood pressure monitor, cholesterol screening analyzer, or other devices (e.g., cellular telephone) not specifically indicated for the management of diabetes mellitus, are regarded as not medically necessary convenience items.

[Capsule Endoscopy \(Camera Pill\)](#)

- Added the SmartPill™ motility testing system as investigational.

[Radiofrequency Ablation \(RFA\) of Tumors](#)

- Clarified for gastrointestinal stromal tumors that RFA is appropriate for the treatment of progression in a single metastatic site, but not in multiple metastatic sites.

### Gene Expression Profiling

- Added Commercial and Medicaid coverage of the Decipher, Oncotype, Prolaris, and ProMark gene/biomarker expression profiling tests for prostate cancer to pre-existing Medicare coverage.

### KYMRIAH™ (tisagenlecleucel)

- Clarified clinical criteria and expanded it from Medicaid to all EmblemHealth benefit plans.

## Pharmacy

See our latest [Formulary Updates](#)

## Medical Technologies Database

The [Medical Technologies Database](#) has been updated. Below is a summary of changes.

### Approved

1. Gene/biomarker expression profiling for prostate cancer (added Commercial and Medicaid to already-covered Medicare)
  - a. Decipher® Prostate
  - b. Oncotype DX
  - c. Prolaris® Prostate Cancer
  - d. ProMark® Proteomic Prognostic Test
2. HeartFlow® digital 3D modeling
3. KYMRIAH™ (tisagenlecleucel) (added Commercial and Medicare to already-covered Medicaid)
4. LUXTERNA™ (voretigene neparvovec-rzyl) (Medicaid only)

### Rejected

1. Cxbladder tests for bladder cancer
  - a. Detect
  - b. Monitor
  - c. Triage
2. LATERA® Absorbable Nasal Implant
3. Per-oral endoscopic myotomy (POEM) for the treatment of swallowing disorders
4. SmartPill™ motility testing system

#### EmblemHealth

55 Water St. New York, NY, 10041



EmblemHealth benefit plans are underwritten by the EmblemHealth companies Group Health Incorporated (GHI), HIP Health Plan of New York (HIP) and HIP Insurance Company of New York.

This email was sent to [hdickman@emblemhealth.com](mailto:hdickman@emblemhealth.com) by EmblemHealth. To ensure delivery to your inbox, please add [EmblemHealth@emblemhealthcommunications.com](mailto:EmblemHealth@emblemhealthcommunications.com) to your address book or safe sender list. If you'd like to unsubscribe from our mailing list, [click here](#). Please note this mailbox is not monitored. Do not respond to this email. If you need assistance, please contact your representative.

Copyright ©2018 EmblemHealth. All Rights Reserved.  
JP42253

[Privacy Policy](#)